Evidence map›Paper›PMID 33567792›Full record

ArticleVaccines2021

Immunomodulatory Role of NK Cells during Antiviral Antibody Therapy.

Mar Naranjo-Gomez, Marine Cahen, Jennifer Lambour, Myriam Boyer-Clavel, Mireia Pelegrin

Open access · goldAbstract read
In one paragraph

Article in Vaccines, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.7field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Mar Naranjo-GomezIGMM, Univ Montpellier, CNRS, Montpellier, France.ORCID 0000-0002-7068-2671
Marine CahenIGMM, Univ Montpellier, CNRS, Montpellier, France.
Jennifer LambourIGMM, Univ Montpellier, CNRS, Montpellier, France.
Myriam Boyer-ClavelMontpellier Ressources Imagerie, Biocampus, Univ Montpellier, CNRS, Montpellier, France.
Mireia PelegrinIGMM, Univ Montpellier, CNRS, Montpellier, France.ORCID 0000-0002-0117-2010
Centre National de la Recherche Scientifique · FR

Funding

Agence Nationale de la Recherche ANR-10-LABX -53-01Ligue Contre le Cancer 157935, RAB19013FFASidaction BI25-1-02278; A014-2-AEQ-08-01
6 · The paper itself

Abstract

Monoclonal antibodies (mAbs) are now considered as a therapeutic approach to prevent and treat severe viral infections. Using a mouse retroviral model, we showed that mAbs induce protective immunity (vaccinal effects). Here, we investigated the role of natural killer (NK) cells on this effect. NK cells are effector cells that are crucial to control viral propagation upon mAb treatment. However, their immunomodulatory activity during antiviral mAb immunotherapies has been little studied. Our data reveal that the mAb treatment of infected mice preserves the functional activation of NK cells. Importantly, functional NK cells play an essential role in preventing immune dysfunction and inducing antiviral protective immunity upon mAb therapy. Thus, NK cell depletion in mAb-treated, viral-infected mice leads to the upregulation of molecules involved in immunosuppressive pathways (i.e., PD-1, PD-L1 and CD39) on dendritic cells and T cells. NK cell depletion also abrogates the vaccinal effects induced by mAb therapy. Our data also reveal a role for IFNγ-producing NK cells in the enhancement of the B-cell responses through the potentiation of the B-cell helper properties of neutrophils. These findings suggest that preserved NK cell functions and counts might be required for achieving mAb-induced protective immunity. They open new prospects for improving antiviral immunotherapies.

Indexed as

antiviral immunityantiviral monoclonal antibodiesB-cell helper neutrophilsCD39immunotherapyinhibitory receptorsNK cellsPD-1PD-L1vaccine-like effects

Identifiers

PMID33567792
PMCPMC7914599
OpenAlexW3127966108

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.